Tan M, Bhadoria AS, Cui F, et al. - Based on the WHO 2015 guidelines, researchers attempted to calculate the proportion of people with chronic hepatitis B virus (HBV) infection eligible for antiviral treatment worldwide. Researchers conducted a systematic review and meta-analysis searching Medline, EMBASE, and the Cochrane databases from January 1, 2007 to January 31, 2018 for studies that characterized HBsAg-positive people in the population or healthcare facilities. In this analysis, 162 studies out of 13,497 were eligible and used for this study. Many of these studies reported people with HBV infection, but few reported information in a way that allowed eligibility for treatment to be evaluated. Around 12–25% of the 257 million people with HBV infection is eligible for treatment in accordance with various guidelines, but about one in ten (26 million) might be in urgent need of treatment due to cirrhosis. Further trials describing people with HBV infection should employ broadly agreed definitions to report on treatment eligibility.